Shares of Eli Lilly closed down more than 4 percent April 17 after the Food and Drug Administration rejected its drug to treat rheumatoid arthritis, according to CNBC.
Shares of Incyte, Lilly’s partner on the drug, baricitinib, closed down nearly 11 percent. Wall Street analysts believed the treatment would have generated more than $1 billion in sales by 2020 if it had been approved, according to Bloomberg data.
Analysts at BMO Capital Markets downgraded Lilly’s stock to underperform from market perform and lowered their price target on the shares to $71 from $73. The analysts called baricitinib’s rejection a “surprising, and significant, setback for Lilly.”
“Overall, we highly doubt that the stated FDA concerns could be addressed without new clinical trials; therefore, we believe the timing for Bari’s U.S. RA launch is most likely pushed back at least three years,” BMO said in a Monday note, adding it lowered its 2017 global sales forecast on the company to $1.6 billion from $2.2 billion.
Our No-Fee Promise On Eli Lilly Lawsuits
You can afford to have our great team of lawyers on your side. When you choose us, it literally costs nothing to get started. We promise you in writing:
- No money to get started
- We pay all case costs and expenses
- No legal fees whatsoever unless you receive a settlement
- Phone calls are always free.
Can I Start An Eli Lilly Claim?
Our lawyers will help you file your lawsuit. To get started, you can:
- Submit the Free Case Review Box on this page, or
- Call (866) 280-4722 any time of day to tell us about your case.
We will listen to your story and answer your questions. If you have claim, we will start immediately.
WARNING: There are strict time deadlines for filing Eli Lilly claims. Call now to get your claim filed and receive a settlement.